Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Assertio Therapeutics ( (ASRT) ) has shared an announcement.
At its recent Annual Meeting, Assertio Therapeutics‘ stockholders approved several key proposals, including an amendment to the 2014 Omnibus Incentive Plan, increasing the number of shares available for issuance by 8,200,000. Additionally, the stockholders elected seven directors to serve until the 2026 Annual Meeting, approved executive compensation, authorized a potential reverse stock split, and ratified Grant Thornton LLP as the independent auditor for 2025. These decisions reflect strategic moves to enhance the company’s operational flexibility and governance structure.
The most recent analyst rating on (ASRT) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.
Spark’s Take on ASRT Stock
According to Spark, TipRanks’ AI Analyst, ASRT is a Neutral.
Assertio Therapeutics’ overall stock score reflects significant challenges in profitability and revenue stabilization, coupled with technical indicators pointing towards a bearish trend. While there are some positive strategic moves and legal settlements, the company’s valuation remains unattractive due to net losses and no dividend yield. Guidance stability offers some reassurance but is overshadowed by operational and financial hurdles.
To see Spark’s full report on ASRT stock, click here.
More about Assertio Therapeutics
Average Trading Volume: 379,495
Technical Sentiment Signal: Sell
Current Market Cap: $58.94M
For an in-depth examination of ASRT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue